ESTRO 2024 - Abstract Book

S1725

Clinical - Lung

ESTRO 2024

Benchmark 2 (%)

Total (n)

Numerator

Denominator

Complied (n)

Percent (%)

All

stage

I-III

Received curative intent RT of ≥54Gy

NSCLC

not

474

2164

21.9

35

undergoing surgery

All stage I-II NSCLC and good performance status (PS) not undergoing surgery

Received curative intent RT of ≥54Gy

114

389

29.3

Received combined platinum-based doublet chemotherapy and radiation therapy

All stage III NSCLC 152

1519

10

All stage III NSCLC not undergoing surgery who receive curative intent RT of ≥54Gy

Received concurrent or sequential chemotherapy

84

105

80

50

All

stage

I-III

Death within 60 days of curative intent RT

NSCLC

with

1

164

0.6

<5

curative intent

Received

Stereotactic

All stage I NSCLC not undergoing surgery All stage I or II NSCLC with curative lung resection All resected NSCLC with N2 disease

Ablative

Body

15

539

2.8

Radiotherapy (SABR)

Received no adjuvant RT

646

734

88

Received adjuvant RT

67

67

100

Received or carboplatin and etoposide with concurrent RT RT delivered with first or second cycle of chemotherapy cisplatin

All limited stage SCLC (LS-SCLC)

90

299

30.1

70

All LS-SCLC who received CRT

46

67

68.7